| Active substance | somatotropin |
| Holder | Novo Nordisk Pharma |
| Status | Running |
| Indication | growth failure in children with achondroplasia/hypochondroplasia |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 11/08/2022 |
Norditropin®
Last updated on 28/09/2022